[1]	Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and down syndrome[J]. Proc Natl Acad Sci U S A, 1985, 82(12):4245-4249. Cited in this article [1]

[2]	Masters CL, Multhaup G, Simms G, et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels[J]. EMBO J, 1985, 4(11):2757-2763. Cited in this article [1]

[3]	Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein[J]. Biochem Biophys Res Commun, 1984, 120(3):885-890. Cited in this article [1]

[4]	Bancher C, Brunner C, Lassmann H, et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease[J]. Brain Res, 1989, 477(1-2):90-99. Cited in this article [1]

[5]	Chen GF, Xu TH, Yan Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development[J]. Acta Pharmacol Sin, 2017, 38(9):1205-1235. Cited in this article [2]

[6]	Chen QS, Kagan BL, Hirakura Y, et al. Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides[J]. J Neurosci Res, 2000, 60(1):65-72. Cited in this article [1]

[7]	Arbor SC, LaFontaine M, Cumbay M, et al. Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores[J]. Yale J Biol Med, 2016, 89(1):5-21. Cited in this article [1]

[8]	Bernstein SL, Dupuis NF, Lazo ND, et al. Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease[J]. Nat Chem, 2009, 1(4):326-331. Cited in this article [1]

[9]	Thakur S, Dhapola R, Sarma P, et al. Neuroinflammation in Alzheimer's disease: current progress in molecular signaling and therapeutics[J]. Inflammation, 2023, 46(1):1-17. Cited in this article [1]

[10]	Chen Z, Zhong C. Oxidative stress in Alzheimer's disease[J]. Neurosci Bull, 2014, 30(2):271-281. Cited in this article [1]

[11]	Reinisalo M, Karlund A, Koskela A, et al. Polyphenol stilbenes: molecular mechanisms of defence against oxidative stress and aging-related diseases[J]. Oxid Med Cell Longev, 2015, 2015:340520. Cited in this article [1]

[12]	Mutter J, Curth A, Naumann J, et al. Does inorganic mercury play a role in Alzheimer's disease? a systematic review and an integrated molecular mechanism[J]. J Alzheimers Dis, 2010, 22(2):357-374. Cited in this article [1]

[13]	Rozga M, Bal W. The Cu(II)/Abeta/human serum albumin model of control mechanism for copper-related amyloid neurotoxicity[J]. Chem Res Toxicol, 2010, 23(2):298-308. Cited in this article [1]

[14]	Lei P, Walker T, Ayton S, et al. Neuroferroptosis in health and diseases[J]. Nat Rev Neurosci, 2025. Cited in this article [1]

[15]	Zhang X, Wang J, Zhang Z, et al. Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies[J]. Transl Neurodegener, 2024, 13(1):40. Cited in this article [1]

[16]	Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein-E Type-4 allele and the risk of Alzheimers-disease in late-onset families[J]. Science, 1993, 261(5123):921-923. Cited in this article [1]

[17]	Liu S, Park S, Allington G, et al. Targeting apolipoprotein E/Amyloid beta binding by peptoid CPO_Abeta17-21 P ameliorates Alzheimer's disease related pathology and cognitive decline[J]. Sci Rep, 2017, 7(1):8009. Cited in this article [1]

[18]	Garai K, Verghese PB, Baban B, et al. The binding of apolipoprotein E to oligomers and fibrils of amyloid-beta alters the kinetics of amyloid aggregation[J]. Biochemistry, 2014, 53(40):6323-6331. Cited in this article [1]

[19]	Ruiz J, Kouiavskaia D, Migliorini M, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor[J]. J Lipid Res, 2005, 46(8):1721-1731. Cited in this article [1]

[20]	Guo JL, Braun D, Fitzgerald GA, et al. Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes[J]. Cell, 2025, 188(1):187-206. Cited in this article [1]

[21]	Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis[J]. Biol Psychiatry, 2015, 77(1):43-51. Cited in this article [1]

[22]	Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates abeta, tau, immunity and lipid processing[J]. Nat Genet, 2019, 51(3):414-430. Cited in this article [1]

[23]	Jiao B, Xiao X, Yuan Z, et al. Associations of risk genes with onset age and plasma biomarkers of Alzheimer's disease: a large case-control study in mainland China[J]. Neuropsychopharmacology, 2022, 47(5):1121-1127. Cited in this article [1]

[24]	Arndt JW, Qian F, Smith BA, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta[J]. Sci Rep, 2018, 8(1):6412. Cited in this article [1]

[25]	Chad JS, Yong Z, Shobha D, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody[J]. Alzheimers Res Ther, 2021, 13(1):80. Cited in this article [1]

[26]	Minton MA, Lo AC, Evans CD, et al. Donanemab in early Alzheimer's disease[J]. New Engl J Med, 2021, 384(18):1691-1704. Cited in this article [1]

[27]	Kim B-H, Kim S, Nam Y, et al. Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives[J]. Transl Neurodegener, 2025, 14(1):6. Cited in this article [1]

[28]	Robakis NK. Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives[J]. Neurobiol Aging, 2011, 32(3):372-379. Cited in this article [1]

[29]	Kadamangudi S, Marcatti M, Zhang WR, et al. Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses[J]. Acta Neuropathol, 2024, 149(1):2. Cited in this article [1]

[30]	Wakeman DR, Weed MR, Perez SE, et al. Intrathecal amyloid-β oligomer administration increases tau phosphorylation in the medial temporal lobe in the African green monkey: a nonhuman primate model of Alzheimer's disease[J]. Neuropathol Appl Neurobiol, 2022, 48(4):e12800. Cited in this article [1]

[31]	Yue F, Feng S, Lu C, et al. Synthetic amyloid-beta oligomers drive early pathological progression of Alzheimer's disease in nonhuman primates[J]. IScience, 2021, 24(10):103207. Cited in this article [1]

[32]	Johnson LV, Leitner WP, Rivest AJ, et al. The Alzheimer's abeta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration[J]. Proc National Acad Sci U S A, 2002, 99(18):11830. Cited in this article [1]

[33]

Mullins RF, Russell SR, Hageman GS, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease[J]. FASEB J, 2000, 14(7):835-846. Cited in this article [2]

[34]	Vilchez D, Saez I, Dillin A, et al. The role of protein clearance mechanisms in organismal ageing and age-related diseases[J]. Nat Commun, 2014, 5:5659. Cited in this article [1]

[35]	Zadka Ł, Sochocka M, Hachiya N, et al. Endocytosis and Alzheimer's disease[J]. GeroScience, 2024, 46(1):71-85. Cited in this article [2]

[36]	Ando K, Brion JP, Stygelbout V, et al. Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains[J]. Acta Neuropathol, 2013, 125(6):861-878. Cited in this article [1]

[37]	Park TE, Singh B, Li H, et al. Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer's disease[J]. Biomaterials, 2015, 38:61-71. Cited in this article [1]

[38]	Wu J, Zhou SL, Pi LH, et al. High glucose induces formation of tau hyperphosphorylation via Cav-1-mTOR pathway: a potential molecular mechanism for diabetes-induced cognitive dysfunction[J]. Oncotarget, 2017, 8(25):40843-40856. Cited in this article [1]

[39]	Mandrekar S, Jiang Q, Lee CYD, et al. Microglia mediate the clearance of soluble aβ through fluid phase macropinocytosis[J]. J Neurosci, 2009, 29(13):4252-4262. Cited in this article [1]

[40]	Prabhudas M, Bowdish D, Drickamer K, et al. Standardizing scavenger receptor nomenclature[J]. J Immunol, 2014, 192(5):1997-2006. Cited in this article [1]

[41]	Gu BJ, Saunders BM, Jursik C, et al. The P2X7-nonmuscle myosin membrane complex regulates phagocytosis of nonopsonized particles and bacteria by a pathway attenuated by extracellular ATP[J]. Blood, 2010, 115(8):1621-1631. Cited in this article [3]

[42]	Gu BJ, Saunders BM, Petrou S, et al. P2X(7) is a scavenger receptor for apoptotic cells in the absence of its ligand, extracellular ATP[J]. J Immunol, 2011, 187(5):2365-2375. Cited in this article [1]

[43]	Gu BJ, Rathsam C, Stokes L, et al. Extracellular ATP dissociates nonmuscle myosin from P2X(7) complex: this dissociation regulates P2X(7) pore formation[J]. Am J Physiol Cell Physiol, 2009, 297(2):C430-439. Cited in this article [2]

[44]	Park YM, Drazba JA, Vasanji A, et al. Oxidized LDL/CD36 interaction induces loss of cell polarity and inhibits macrophage locomotion[J]. Mol Biol Cell, 2012, 23(16):3057-3068. Cited in this article [1]

[45]	Gomez CP, Descoteaux A. Moesin and myosin IIA modulate phagolysosomal biogenesis in macrophages[J]. Biochem Biophys Res Commun, 2018, 495(2):1964-1971. Cited in this article [1]

[46]	Rayaprolu S, Gao T, Xiao H, et al. Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer's disease[J]. Mol Neurodegener, 2020, 15(1):28. Cited in this article [1]

[47]	Gu BJ, Wiley JS. P2X7 as a scavenger receptor for innate phagocytosis in the brain[J]. Br J Pharmacol, 2018, 175(22):4195-4208. Cited in this article [1]

[48]	Gu BJ, Wiley JS. Broad applications of multi-colour time-resolved flow cytometry[C]. In: Schmid I, ed. Flow Cytometry: Recent Perspectives. Croatia; InTech 2012:185-202. Cited in this article [1]

[49]	Gu BJ, Sun C, Fuller S, et al. A quantitative method for measuring innate phagocytosis by human monocytes using real-time flow cytometry[J]. Cytometry A, 2014, 85(4):313-321. Cited in this article [2]

[50]

Gu BJ, Duce JA, Valova VA, et al. P2X7 receptor-mediated scavenger activity of mononuclear phagocytes toward non-opsonized particles and apoptotic cells is inhibited by serum glycoproteins but remains active in cerebrospinal fluid[J]. J Biol Chem, 2012, 287(21):17318-17330. Cited in this article [2]

[51]	Lovelace MD, Gu BJ, Eamegdool SS, et al. P2X7 receptors mediate innate phagocytosis by human neural precursor cells and neuroblasts[J]. Stem Cells, 2015, 33(2):526-541. Cited in this article [2]

[52]	Vessey KA, Gu BJ, Jobling AI, et al. Loss of Function of P2X7 receptor scavenger activity in aging mice: a novel model for investigating the early pathogenesis of age-related macular degeneration[J]. Am J Pathol, 2017, 187(8):1670-1685. Cited in this article [1]

[53]	De Maeyer RPH, Chambers ES. The impact of ageing on monocytes and macrophages[J]. Immunol Lett, 2021, 230:1-10. Cited in this article [1]

[54]	Hampton K, Hellmich C, Maynard RS, et al. LC3-Associated phagocytosis is impaired in bone marrow macrophages during ageing leading to defective processing of apoptotic cells and suppression of sting activation[J]. Blood, 2022, 140(Supplement 1):5759-5759. Cited in this article [1]

[55]	Li W. Phagocyte dysfunction, tissue aging and degeneration[J]. Ageing Res Rev, 2013, 12(4):1005-1012. Cited in this article [1]

[56]	Kumakura S, Yamaguchi Y, Murakawa Y, et al. Effect of cytokines and hyperthermia on phagocytosis and phosphatidylserine externalization: implication for the pathophysiology of hemophagocytic syndrome[J]. Ann Clin Lab Sci, 2018, 48(3):314-322. Cited in this article [1]

[57]	Protsiv M, Ley C, Lankester J, et al. Decreasing human body temperature in the United States since the industrial revolution[J]. Elife, 2020, 9:e49555. Cited in this article [1]

[58]	Wang J, Gu BJ, Masters CL, et al. A systemic view of Alzheimer disease - insights from amyloid-beta metabolism beyond the brain[J]. Nat Rev Neurol, 2017, 13(10):612-623. Cited in this article [1]

[59]	Gu BJ, Huang X, Ou A, et al. Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease[J]. Acta Neuropathol, 2016, 132(3):377-389. Cited in this article [1]

[60]	Huang X, Fowler C, Li Y, et al. Clearance and transport of amyloid beta by peripheral monocytes correlate with Alzheimer's disease progression[J]. Nat Commun, 2024, 15(1):7998. Cited in this article [1]

[61]	Huang X, Li Y, Fowler C, et al. Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease[J]. Alzheimers Dement, 2022, 19(5):2084-2094. Cited in this article [1]

[62]	Li Y, Huang X, Fowler C, et al. Identification of leukocyte surface P2X7 as a biomarker associated with Alzheimer's disease[J]. Int J Mol Sci, 2022, 23(14):7867. Cited in this article [1]

[63]	Gu BJ, Sluyter R, Skarratt KK, et al. An Arg307 to gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor[J]. J Biol Chem, 2004, 279(30):31287-31295. Cited in this article [1]

[64]	Gu BJ, Field J, Dutertre S, et al. A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis[J]. Hum Mol Genet, 2015, 24(19):5644-5654. Cited in this article [1]

[65]	Sadovnick AD, Gu BJ, Traboulsee AL, et al. Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis[J]. Hum Mutat, 2017, 38(6):736-744. Cited in this article [1]

[66]	Gu BJ, Baird PN, Vessey KA, et al. A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration[J]. FASEB J, 2013, 27(4):1479-1487. Cited in this article [1]

[67]	Gu BJ, Huang X, Avula PK, et al. Deficits in monocyte function in age related macular degeneration: a novel systemic change associated with the disease[J]. Front Med, 2021, 8:634177. Cited in this article [1]

[68]	Wiley JS, Gu BJ. A new role for the P2X7 receptor: a scavenger receptor for bacteria and apoptotic cells in the absence of serum and extracellular ATP[J]. Purinergic Signal, 2012, 8(3):579-586. Cited in this article [1]

[69]	Leeson HC, Kasherman MA, Chan-Ling T, et al. P2X7 receptors regulate phagocytosis and proliferation in adult hippocampal and SVZ neural progenitor cells: implications for inflammation in neurogenesis[J]. Stem Cells, 2018, 36(11):1764-1777. Cited in this article [1]

[70]	Hu Z, Yang B, Mo X, et al. Mechanism and regulation of autophagy and its role in neuronal diseases[J]. Mol Neurobiol, 2015, 52(3):1190-1209. Cited in this article [1]

[71]	Giong HK, Hyeon SJ, Lee JG, et al. Tau accumulation is cleared by the induced expression of VCP via autophagy[J]. Acta Neuropathol, 2024, 148(1):46. Cited in this article [1]

[72]	Gorantla NV, Chinnathambi S. Autophagic pathways to clear the tau aggregates in Alzheimer's disease[J]. Cell Mol Neurobiol, 2021, 41(6):1175-1181. Cited in this article [1]

[73]	NKrance SH, Wu CY, Chan ACY, et al. Endosomal-lysosomal and autophagy pathway in Alzheimer's disease: a systematic review and meta-analysis[J]. J Alzheimers Dis, 2022, 88(4):1279-1292. Cited in this article [1]

[74]	Kerr JS, Adriaanse BA, Greig NH, et al. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms[J]. Trends Neurosci, 2017, 40(3):151-166. Cited in this article [1]

[75]	Martínez RAS, Pinky PD, Harlan BA, et al. GTP energy dependence of endocytosis and autophagy in the aging brain and Alzheimer's disease[J]. GeroScience, 2023, 45(2):757-780. Cited in this article [1]

[76]	MSilva DF, Esteves AR, Oliveira CR, et al. Mitochondrial metabolism power SIRT2-dependent deficient traffic causing Alzheimer's-disease related pathology[J]. Mol Neurobiol, 2017, 54(6):4021-4040. Cited in this article [1]

[77]	Fairley LH, Kei Onn L, Jia Hui W, et al. Mitochondrial control of microglial phagocytosis by the translocator protein and hexokinase 2 in Alzheimer's disease[J]. Proc National Acad Sci U S A, 2023, 120(8):1-12. Cited in this article [1]

[78]	Zhang H, Wang H, Gao F, et al. TSPO deficiency accelerates amyloid pathology and neuroinflammation by impairing microglial phagocytosis[J]. Neurobiol Aging, 2021, 106:292-303. Cited in this article [1]

[79]	Jadala C, Robo MT, Richardson TI, et al. Exploring Class‐II PI3K inhibition for the treatment of Alzheimer's disease: virtual screening for PI3KC2A inhibitors[J]. Alzheimers Amp Dement, 2024, 20(S6):1-2. Cited in this article [1]

[80]	Yoon Sun C, Oh-hoon K, Hyun Geun O, et al. Justicidin a reduces β-Amyloid via inhibiting endocytosis of β-Amyloid precursor protein[J]. Biomol Ther, 2019, 27(3):276-282. Cited in this article [1]

[81]	Cole GM, Yang F, Lim GP, et al. A rationale for curcuminoids for the prevention or treatment of Alzheimer's disease[J]. Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents, 2003, 3(1):15. Cited in this article [1]

[82]	Mizwicki MT, Menegaz D, Zhang J, et al. Genomic and nongenomic signaling induced by 1α25(OH)2-Vitamin D3 promotes the recovery of Amyloid-β phagocytosis by Alzheimer's disease macrophages[J]. J Alzheimers Dis, 2012, 29(1):51-62. Cited in this article [1]

[83]	Mizwicki MT, Liu G, Fiala M, et al. 1α25-Dihydroxyvitamin D3 and Resolvin D1 retune the balance between Amyloid-β phagocytosis and inflammation in Alzheimer's disease patients[J]. J Alzheimers Dis, 2013, 34(1):155-170. Cited in this article [1]

[84]	Landgraf P, Wahle P, Pape HC, et al. The survival-promoting peptide Y-P30 enhances binding of pleiotrophin to syndecan-2 and -3 and supports its neuritogenic activity[J]. J Biol Chem, 2008, 283(36):25036-25045. Cited in this article [1]

[85]	Bellizzi MJ, Hammond JW, Li H, et al. The mixed-lineage kinase inhibitor URMC-099 protects hippocampal synapses in experimental autoimmune encephalomyelitis[J]. eNeuro, 2018, 5(6): ENEURO.0245-18.2018. Cited in this article [1]

[86]	Tajbakhsh A, Read M, Barreto GE, et al. Apoptotic neurons and amyloid-beta clearance by phagocytosis in Alzheimer's disease: pathological mechanisms and therapeutic outlooks[J]. Eur J Pharmacol, 2021, 895:173873. Cited in this article [1]

[87]	Yang S, Du Y, Zhao X, et al. Cannabidiol enhances microglial beta-amyloid peptide phagocytosis and clearance via vanilloid family type 2 channel activation[J]. Int J Mol Sci, 2022, 23(10):5367. Cited in this article [1]

[88]	Fernandes SM, Mayer J, Nilsson P, et al. How close is autophagy-targeting therapy for Alzheimer's disease to clinical use? a summary of autophagy modulators in clinical studies[J]. Front Cell Dev Biol, 2025, 12:1520949. Cited in this article [1]

[89]	Singh A, Kumar A. Microglial inhibitory mechanism of coenzyme Q10 against abeta (1-42) induced cognitive dysfunctions: possible behavioral, biochemical, cellular, and histopathological alterations[J]. Front Pharmacol, 2015, 6:268. Cited in this article [1]

[90]	Li W, Wang S zhang H, et al. Honokiol restores microglial phagocytosis by reversing metabolic reprogramming[J]. J Alzheimers Dis, 2021, 82(4):1475-1485. Cited in this article [1]

[91]	Ma M, Wang J, Guo K, et al. A self-reinforced "microglia energy modulator" for synergistic amyloid-β clearance in Alzheimer's disease model[J]. Angew Chem Int Ed Endl, 2025, 137(8):1-9. Cited in this article [1]

[92]	Cummings JL, Zhou Y, Lee G, et al. Alzheimer's disease drug development pipeline: 2025[J]. Alzheimers Dement (N Y), 2025, 11(2):e70098. Cited in this article [1]

[93]	Stepanov YV, Golovynska I, Zhang R, et al. Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer's disease[J]. Alzheimers Res Ther, 2022, 14(1):84. Cited in this article [1]

[94]	NLi Q, Peng J, Luo Y, et al. Far infrared light irradiation enhances Aβ clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer's disease-like mice[J]. J Neuroinflammation, 2022, 19(1):145. Cited in this article [1]